Is EVFM Stock the Next Big Squeeze?

$Evofem Biosciences (EVFM.US)$ stock only recently became well-known on Wall Street. After the U.S. Supreme Court overturned Roe vs. Wade, the rush on contraceptives propelled the microcap biotech stock to new highs. But just over a week later, EVFM stock is making headlines for different reasons. Some experts predict it will be among the market’s next gamma squeezes.
Fintel ranks EVFM stock at the top of its gamma squeeze leaderboard for this week. The company boasts a high gamma squeeze score of 99.50. Its net call open interest (OI) percentage of float is also 37.98%. That’s substantially higher than the second stock on the list, $Revlon (REV.US)$ , at 23.75%. While Revlon and third-place stock $Clovis Oncology (CLVS.US)$ have advanced steadily in the rankings since last week, EVFM stock is new to the leaderboard.
$S&P 500 Index (.SPX.US)$ $SPDR S&P 500 ETF (SPY.US)$ $AMC Entertainment (AMC.US)$